Overview

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Status:
Not yet recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC